FDA approves Mimrylo for polycythemia vera, a rare blood cancer
Reported bySTAT News ↗·Sourced by Goodlede
The FDA approved rusfertide (Mimrylo), a weekly injection developed by Protagonist Therapeutics and sold by Takeda, to treat polycythemia vera, a chronic blood cancer in which overproduction of red blood cells thickens blood and increases risk of heart attacks, strokes, and blood clots.
Goodlede runs a two-pass source check on every story: one pass finds it, a second skeptical pass re-verifies the claim and writes what it doesn’t prove. This is a source check, not an independent fact-check — confirm anything important at the link above.
Read the full story at STAT News
Read original story ↗More good news, verified daily.
Goodlede covers positive developments across science, nature, rights, and human achievement — verified before they appear. No hype, no roundups, no PR wires.
© 2026 Wag Media, LLC
More from Goodlede